ArticleDiscover oncology2026
Machine learning for predicting liver metastasis in colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimTo evaluate the performance of machine learning models in predicting liver metastasis in colorectal cancer (CRC) patients using the SEER database and external validation from Ningbo No.2 Hospital.
methodsThe data on patients with colorectal cancer were obtained from Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2023. Patients were classified into training (n = 29017) and testing sets (n = 12437). The data were used to build eight machine learning models to predict liver metastasis in colorectal cancer patients. A total of 11 clinical variables were entered into these models. Model performance was measured with the area under the receiver operating characteristic curve (ROC) and area under precision-recall curve (AUPR). The models were visualized and interpreted using the SHAP method.
resultsIn the SEER database cohort, the incidence of liver metastasis was 7.2% (2977/41,454). Of the eight machine learning models, Gradient Boosting (GB) had the best AUC (0.837) and AUPR (0.294). Upon external validation, the GB model achieved an AUC of 0.730 and an AUPR of 0.278. We explored the significance of features in the model through SHAP analysis. CEA, N stage and T stage were the heavily weighted factors used by the GB. An online calculator was developed for clinical use.
conclusionThe GB model demonstrates robust predictive performance for liver metastasis in CRC, validated internally and externally, and presents a potentially valuable tool for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.